Summary
Overview
Work History
Education
Skills
Publications
Timeline
Volunteer
Shaye Stamatis

Shaye Stamatis

Biotech/pharma Executive
San Francisco,CA

Summary

A drug development executive and leader with over 20 years of experience in infectious diseases and global health in academic, biotech, pharma and NGO settings. Deep international experience, leading public-private partnerships, driving global programs, multifunctional global teams, raising funds and building a biotech startup. A strategic thinker with foresight and vision that consistently demonstrates judgment, communication skills, and diplomacy.

Overview

22
22
years of professional experience
2
2
Languages

Work History

Co-founder, President & CEO

Lifeguard Biosciences, Inc.
01.2022 - Current
  • Established Lifeguard Biosciences, Inc., an early stage biotech company focused on developing therapeutics to tackle opioid overdose
  • Responsible for strategy, operations, fundraising, investor relations, business development, financial management, strategic alliances in public and private sector, negotiations, executive presentations and governance.

Head of Public Health

GlaxoSmithKline
San Francisco
01.2018 - 01.2022
  • Led Public Health in China for GSK's Global Health R&D Unit
  • Responsible for strategy and oversight of public private partnerships, strategic alliances with key stakeholders to support GSK's development pipeline and created new initiatives and partnerships to foster innovation, performance and trust in China
  • Co-led establishment of GSK's Institute for Infectious Diseases and Public Health, leading the Public Health arm of the Institute and the Tsinghua School of Medicine-GSK Center for Global Health.

Senior Director, Strategy & Partnership

GlaxoSmithKline
San Francisco
01.2016 - 01.2018
  • Oversight of strategy and partnership for infectious diseases and engagement efforts in China
  • Member of GSKs Infectious Diseases Leadership Team, responsible for establishing public-private partnerships with key stakeholders for GSK’s Institute for Infectious Diseases and Public Health and creating a platform to bring together academics, governments, healthcare providers, regulators, philanthropists, industry, NGOs and community in support of China’s public health agenda
  • Established Center for Global Health through partnership with Tsinghua University in Beijing and associated programs to build clinical drug development and regulatory science and AI capabilities.

Strategic Program Director

HIV Cure Initiative
San Francisco CA
01.2015 - 01.2016
  • A grass roots organization started by Francoise Barre-Sinoussi (Nobel Laureate) and Jack Whitescarver (Former Head of Obama Administration AIDS Fund)
  • Reporting to steering committee, governance board and fiscal sponsor, responsible for driving momentum and building public private partnerships through international alliance of leading scientific, governmental, philanthropic, and industrial organizations that have collectively resolved to identify, test, and distribute interventions that will lead to drug-free remission (or “cure”) in HIV-infected individuals
  • Areas of focus include strategy, stakeholder engagement, business development, advocacy, branding and development operational infrastructure.

Director, Portfolio & Project Management

PATH
San Francisco, CA
01.2014 - 01.2016
  • Deputy to drug development platform lead with oversight of strategy, planning, and management for four program areas; portfolio and project management, regulatory affairs, quality assurance, and business development
  • Led drug platform strategy refresh, established drug-focused business development team and internal processes and tools for forecasting and securing new opportunities with respect to global health drug development portfolio of work
  • Successfully funded and established PATH’s first HIV drug program
  • Relationship manager for key partners internal and external to PATH
  • Responsibilities and memberships included PATH Drug Development Leadership Team, Bill & Melinda Gates Foundation Global Health Regulatory Leadership Team, PATH Human Subjects Research Advisory Committee, PATH Portfolio & Project Management Advisory Committee, PATH QA and Regulatory Task Force.

Associate Director, Project Management, QA & Regulatory

PATH (formerly OneWorld Health)
San Francisco, CA
01.2010 - 01.2014
  • Reporting to CEO with oversight of all Project management, Regulatory and QA for OneWorld Health (and later PATH), spanning various therapeutic areas including enteric diseases, malaria, visceral leishmaniasis
  • Established OneWorld Health’s PMO, managed $150M+ portfolio of projects with cross-functional global teams, including first in class diarrhea drug (from discovery through phase II clinical trials)
  • Strategy and sustainability planning for organization prior to acquisition by PATH in 2012
  • Project team lead for Amphotericin B project, member of drug development management team, Global Health Regulatory Team (Bill & Melinda Gates Foundation)
  • Recipient of PATH 2012 Vision Award for leadership role in acquisition of OneWorld Health by PATH.

Project Manager

OneWorld Health
01.2009 - 01.2010
  • Management of enteric diseases portfolio of projects with cross-functional global teams and partners, including a $46M grant-funded program from discovery through pre-IND stage.

Sr Research Associate

Amgen, Inc.
01.2005 - 01.2009
  • Development of in-house human islet transplant program for assessing beta cell protection and efficacy of type II diabetes compounds
  • Program supported metabolic disorders department and included in-vivo, molecular and cell biology assays to determine compound efficacy and candidates for further development.

Life Science Research Associate II

Stanford University, School of Medicine
01.2003 - 01.2005
  • Pediatric infectious disease research investigating the molecular virology of varicella zoster virus pathogenesis and immunity through human tissue transplant model and other assays
  • Clinical research of human cytomegalovirus immunity, and the molecular biology and immunology of influenza infection
  • Management of influenza clinical core lab.

Life Science Research Associate I

Stanford University, School of Medicine
01.2002 - 01.2003
  • Basic & Clinical Research investigating varicella zoster virus (VZV) immunity and pathogenesis, human cytomegalovirus (HCMV) immunity, and the molecular biology and immunology of influenza infection.

Education

Honours. Sc. - Integrated Masters Degree

University of Melbourne
Australia

B.Sc. - Zoology

University of Melbourne
Australia

PMP Certification -

University of California, Berkeley Extension

Climate Change and Health Certification -

Yale University

Skills

    Leadership

undefined

Publications

  • Mutagenesis of Varicella-Zoster Virus Glycoprotein I (gI) Identifies a Cysteine Residue Critical for gE/gI Heterodimer Formation, gI Structure, and Virulence in Skin Cells, Oliver SL, Sommer MH, Reichelt M, Rajamani J, Vlaycheva-Beisheim L, Stamatis S, Cheng J, Jones C, Zehnder J, Arvin AM, J.Virol., 2011-09-01
  • Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine, Zeman, A.M., Holmes, T.H., Stamatis, S., Tu, W., He, X., Bouvier, N., Kemble, G., Greenberg, H., Lewis, D.B., Arvin, A.M., Dekker, C.L., The Pediatric Infectious Disease Journal, 2007-02-01
  • Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection, Berarducci B, Ikoma M, Stamatis S, Sommer M, Grose C, Arvin AM, J Virol., 2006-10-01
  • Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model, Zerboni, L., Hinchliffe, S., Sommer, M.H., Ito, H., Besser, J., Stamatis, S., Cheng, J.J., DiStefano, D., Kraiouchkine, N., Shaw, A., Arvin, A.M., Virology, 2005-12-01
  • T-Cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection, Schaap, A., Fortin, J.F., Sommer, M.H., Zerboni, L., Stamatis, S., Ku, C.C., Nolan, G.P., and Arvin, A.M., J. Virol., 2005-10-01
  • Varicella-zoster virus glycoprotein I: a small region in the ectodomain essential for virulence in skin and virion maturation and envelopment in vitro, Vlaycheva, L.A., Stamatis, S., Cheng, J.J., Sommer, M.H., Arvin, A.M., 2005-01-01
  • Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region, Jones, J.O., Sommer, M.H., Stamatis, S., and Arvin, A.M., J Virol., 2005-03-01
  • Functions of the C-terminal domain of varicella zoster virus glycoprotein E in viral replication in vitro and skin and T cell tropism in vivo, Moffatt, J., Mo, C., Cheng J.J., Sommer, M.H., Zerboni, L., Stamatis, S., Arvin, A.M., J. Virol., 2004-11-01
  • The expression of the insulin-like growth factor-II gene in the uterus of the tammar wallaby during diapause and pregnancy, Stamatis, S., Thesis publication, Brownless Biomedical Library, University of Melbourne, 2001-01-01

Timeline

Co-founder, President & CEO

Lifeguard Biosciences, Inc.
01.2022 - Current

Head of Public Health

GlaxoSmithKline
01.2018 - 01.2022

Senior Director, Strategy & Partnership

GlaxoSmithKline
01.2016 - 01.2018

Strategic Program Director

HIV Cure Initiative
01.2015 - 01.2016

Director, Portfolio & Project Management

PATH
01.2014 - 01.2016

Associate Director, Project Management, QA & Regulatory

PATH (formerly OneWorld Health)
01.2010 - 01.2014

Project Manager

OneWorld Health
01.2009 - 01.2010

Sr Research Associate

Amgen, Inc.
01.2005 - 01.2009

Life Science Research Associate II

Stanford University, School of Medicine
01.2003 - 01.2005

Life Science Research Associate I

Stanford University, School of Medicine
01.2002 - 01.2003

Honours. Sc. - Integrated Masters Degree

University of Melbourne

B.Sc. - Zoology

University of Melbourne

PMP Certification -

University of California, Berkeley Extension

Climate Change and Health Certification -

Yale University
Shaye StamatisBiotech/pharma Executive